News
MyChesCo on MSN1d
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer TrialHigh-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...
Verywell Health on MSN5h
Enhertu Shows Promise as First-Line Treatment for Metastatic Breast CancerA combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...
Clinical Trials Arena on MSN13h
Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 monthsBoehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...
But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...
MedPage Today on MSN9h
Novel TKI Highly Active in HER2-Mutant Lung CancerThe investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...
Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...
The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...
AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...
Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of adult ...
Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback